Diabetes is the leading cause of non-traumatic limb amputation in sub-Saharan Africa and oral antidiabetes drugs are the main stay of type 2 diabetes (T2DM) therapy. Many published studies have indicated the beneficial effects of pharmaceutical care (PC) at improving the treatment outcomes of T2DM patients. This study evaluated the effect of PC intervention on the daily doses of oral antidiabetes drugs. A randomized controlled intervention study was conducted using ambulatory T2DM patients who gave their informed consent and met the inclusion criteria. Patients were randomly assigned into control and intervention group in a single blind manner and followed up for a period of 12 months. Patients in control group received the usual care while those in intervention group received PC interventions. Outcome measure was the mean dose of oral antidiabetes drugs used by patients in the hospital and readings were taking at the onset and end of the intervention period. Descriptive and inferential statistics were used for data analysis at p<0.05 level of significance. A total of 124 T2DM patients participated in the study until the end, and were evenly distributed within the two groups. Glibenclamide and metformin constitutes 91% of all the oral antidiabetes drugs used. The mean daily dose of glibenclamide dropped from 9.0±2.9 to 5.4±1.4, while that of metformin dropped from 1900±0.5 mg to 1400±0.2 mg. p= 0.021, n= 61. Due to the expensive nature of the newer oral antidiabetes drugs e.g. thiazolidinediones; they were not consistent in the prescriptions throughout the study period while the value f aspirin remained unchanged. The study demonstrated that 12 months PC interventions lead to reduction of mean daily dose of oral antidiabetes agents. This suggests improvement in clinical outcomes, patients’ quality of life, and reduction in the cost of therapy.